227 related articles for article (PubMed ID: 35979371)
1. Genomic alteration of MTAP/CDKN2A predicts sarcomatoid differentiation and poor prognosis and modulates response to immune checkpoint blockade in renal cell carcinoma.
Xu W; Anwaier A; Liu W; Wei G; Su J; Tian X; Xia J; Qu Y; Zhao J; Zhang H; Ye D
Front Immunol; 2022; 13():953721. PubMed ID: 35979371
[TBL] [Abstract][Full Text] [Related]
2. Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma.
Bakouny Z; Braun DA; Shukla SA; Pan W; Gao X; Hou Y; Flaifel A; Tang S; Bosma-Moody A; He MX; Vokes N; Nyman J; Xie W; Nassar AH; Abou Alaiwi S; Flippot R; Bouchard G; Steinharter JA; Nuzzo PV; Ficial M; Sant'Angelo M; Forman J; Berchuck JE; Dudani S; Bi K; Park J; Camp S; Sticco-Ivins M; Hirsch L; Baca SC; Wind-Rotolo M; Ross-Macdonald P; Sun M; Lee GM; Chang SL; Wei XX; McGregor BA; Harshman LC; Genovese G; Ellis L; Pomerantz M; Hirsch MS; Freedman ML; Atkins MB; Wu CJ; Ho TH; Linehan WM; McDermott DF; Heng DYC; Viswanathan SR; Signoretti S; Van Allen EM; Choueiri TK
Nat Commun; 2021 Feb; 12(1):808. PubMed ID: 33547292
[TBL] [Abstract][Full Text] [Related]
3. Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade.
Motzer RJ; Banchereau R; Hamidi H; Powles T; McDermott D; Atkins MB; Escudier B; Liu LF; Leng N; Abbas AR; Fan J; Koeppen H; Lin J; Carroll S; Hashimoto K; Mariathasan S; Green M; Tayama D; Hegde PS; Schiff C; Huseni MA; Rini B
Cancer Cell; 2020 Dec; 38(6):803-817.e4. PubMed ID: 33157048
[TBL] [Abstract][Full Text] [Related]
4. Treatments, Outcomes, and Validity of Prognostic Scores in Patients With Sarcomatoid Renal Cell Carcinoma: A 20-Year Single-Institution Experience.
Korenbaum C; Pierard L; Thiéry A; Story F; Lindner V; Lang H; Kurtz JE; Barthélémy P
Clin Genitourin Cancer; 2018 Jun; 16(3):e577-e586. PubMed ID: 29395949
[TBL] [Abstract][Full Text] [Related]
5. Genomic landscape of metastatic breast cancer (MBC) patients with methylthioadenosine phosphorylase (
Bou Zerdan M; Ashok Kumar P; Haroun E; Srivastava N; Ross J; Sivapiragasam A
Oncotarget; 2023 Mar; 14():178-187. PubMed ID: 36913304
[TBL] [Abstract][Full Text] [Related]
6. Genomic landscape of non-small-cell lung cancer with methylthioadenosine phosphorylase (MTAP) deficiency.
Ashok Kumar P; Graziano SL; Danziger N; Pavlick D; Severson EA; Ramkissoon SH; Huang RSP; Decker B; Ross JS
Cancer Med; 2023 Jan; 12(2):1157-1166. PubMed ID: 35747993
[TBL] [Abstract][Full Text] [Related]
7. PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation.
Joseph RW; Millis SZ; Carballido EM; Bryant D; Gatalica Z; Reddy S; Bryce AH; Vogelzang NJ; Stanton ML; Castle EP; Ho TH
Cancer Immunol Res; 2015 Dec; 3(12):1303-7. PubMed ID: 26307625
[TBL] [Abstract][Full Text] [Related]
8. A genomic mutation spectrum of collecting duct carcinoma in the Chinese population.
Zhang H; Lu X; Huang G; Hua M; Zhang W; Wang T; Huang L; Wang Z; Chen Q; Li J; Yang Q; Yang G
BMC Med Genomics; 2022 Jan; 15(1):1. PubMed ID: 34980126
[TBL] [Abstract][Full Text] [Related]
9. Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5.
Mavrakis KJ; McDonald ER; Schlabach MR; Billy E; Hoffman GR; deWeck A; Ruddy DA; Venkatesan K; Yu J; McAllister G; Stump M; deBeaumont R; Ho S; Yue Y; Liu Y; Yan-Neale Y; Yang G; Lin F; Yin H; Gao H; Kipp DR; Zhao S; McNamara JT; Sprague ER; Zheng B; Lin Y; Cho YS; Gu J; Crawford K; Ciccone D; Vitari AC; Lai A; Capka V; Hurov K; Porter JA; Tallarico J; Mickanin C; Lees E; Pagliarini R; Keen N; Schmelzle T; Hofmann F; Stegmeier F; Sellers WR
Science; 2016 Mar; 351(6278):1208-13. PubMed ID: 26912361
[TBL] [Abstract][Full Text] [Related]
10. Sarcomatoid mesothelioma originating from mesothelioma in situ: are methylthioadenosine phosphorylase loss and CDKN2A homozygous deletion poor prognostic factors for preinvasive mesothelioma?
Nishikubo M; Jimbo N; Tanaka Y; Tachihara M; Itoh T; Maniwa Y
Virchows Arch; 2022 Aug; 481(2):307-312. PubMed ID: 35043235
[TBL] [Abstract][Full Text] [Related]
11. Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors.
Iacovelli R; Ciccarese C; Bria E; Bracarda S; Porta C; Procopio G; Tortora G
Eur J Cancer; 2020 Sep; 136():195-203. PubMed ID: 32712550
[TBL] [Abstract][Full Text] [Related]
12. Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients.
Derosa L; Routy B; Fidelle M; Iebba V; Alla L; Pasolli E; Segata N; Desnoyer A; Pietrantonio F; Ferrere G; Fahrner JE; Le Chatellier E; Pons N; Galleron N; Roume H; Duong CPM; Mondragón L; Iribarren K; Bonvalet M; Terrisse S; Rauber C; Goubet AG; Daillère R; Lemaitre F; Reni A; Casu B; Alou MT; Alves Costa Silva C; Raoult D; Fizazi K; Escudier B; Kroemer G; Albiges L; Zitvogel L
Eur Urol; 2020 Aug; 78(2):195-206. PubMed ID: 32376136
[TBL] [Abstract][Full Text] [Related]
13. Molecular determinants of response to PD-L1 blockade across tumor types.
Banchereau R; Leng N; Zill O; Sokol E; Liu G; Pavlick D; Maund S; Liu LF; Kadel E; Baldwin N; Jhunjhunwala S; Nickles D; Assaf ZJ; Bower D; Patil N; McCleland M; Shames D; Molinero L; Huseni M; Sanjabi S; Cummings C; Mellman I; Mariathasan S; Hegde P; Powles T
Nat Commun; 2021 Jun; 12(1):3969. PubMed ID: 34172722
[TBL] [Abstract][Full Text] [Related]
14. The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma.
McKay RR; Bossé D; Xie W; Wankowicz SAM; Flaifel A; Brandao R; Lalani AA; Martini DJ; Wei XX; Braun DA; Van Allen E; Castellano D; De Velasco G; Wells JC; Heng DY; Fay AP; Schutz FA; Hsu J; Pal SK; Lee JL; Hsieh JJ; Harshman LC; Signoretti S; Motzer RJ; Feldman D; Choueiri TK
Cancer Immunol Res; 2018 Jul; 6(7):758-765. PubMed ID: 29748390
[TBL] [Abstract][Full Text] [Related]
15. Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma.
Worsham MJ; Chen KM; Tiwari N; Pals G; Schouten JP; Sethi S; Benninger MS
Arch Otolaryngol Head Neck Surg; 2006 Apr; 132(4):409-15. PubMed ID: 16618910
[TBL] [Abstract][Full Text] [Related]
16. The significance of sarcomatoid and rhabdoid dedifferentiation in renal cell carcinoma.
Hahn AW; Lebenthal J; Genovese G; Sircar K; Tannir NM; Msaouel P
Cancer Treat Res Commun; 2022; 33():100640. PubMed ID: 36174377
[TBL] [Abstract][Full Text] [Related]
17. Renal Cell Carcinoma with Sarcomatoid Features: Finally New Therapeutic Hope?
Pichler R; Compérat E; Klatte T; Pichler M; Loidl W; Lusuardi L; Schmidinger M
Cancers (Basel); 2019 Mar; 11(3):. PubMed ID: 30934624
[TBL] [Abstract][Full Text] [Related]
18. Early Clinical Success of MTA-Cooperative PRMT5 Inhibitors for the Treatment of CDKN2A/MTAP-Deleted Cancers.
Mulvaney KM
Cancer Discov; 2023 Nov; 13(11):2310-2312. PubMed ID: 37909092
[TBL] [Abstract][Full Text] [Related]
19. Integrated Molecular Characterization of Fumarate Hydratase-deficient Renal Cell Carcinoma.
Sun G; Zhang X; Liang J; Pan X; Zhu S; Liu Z; Armstrong CM; Chen J; Lin W; Liao B; Lin T; Huang R; Zhang M; Zheng L; Yin X; Nie L; Shen P; Zhao J; Zhang H; Dai J; Shen Y; Li Z; Liu J; Chen J; Liu J; Wang Z; Zhu X; Ni Y; Qin D; Yang L; Chen Y; Wei Q; Li X; Zhou Q; Huang H; Yao J; Chen N; Zeng H
Clin Cancer Res; 2021 Mar; 27(6):1734-1743. PubMed ID: 33414138
[TBL] [Abstract][Full Text] [Related]
20.
Adib E; Nassar AH; Akl EW; Abou Alaiwi S; Nuzzo PV; Mouhieddine TH; Sonpavde G; Haddad RI; Mouw KW; Giannakis M; Hodi FS; Shukla SA; Gusev A; Braun DA; Choueiri TK; Kwiatkowski DJ
Clin Cancer Res; 2021 Jul; 27(14):4025-4035. PubMed ID: 34074656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
